Sacha Paynter from Bristol has won the United Kingdom Acquired Brain Injury Forum (UKABIF) Film Award for her film ‘Talking Benefits’, sponsored by Cygnet Health Care.
Sacha’s short film looks at the importance of neurorehabilitation for individuals who have had an Acquired Brain Injury (ABI). The film is based on Sacha’s personal family experiences of ABI, and being a carer for both parents who had a brain injury at different times in her life. Sacha’s father had a brain aneurysm when she was a teenager, which sadly resulted in his death, and her mother had a stroke a few years ago.
Commenting on film Sacha said: “My mum received neurorehabilitation in hospital and it was really successful. It’s essential that people have early access to neurorehabilitation following a brain injury like a stroke or an aneurysm, and I’ve seen the wonders that neurorehabilitation can do for an ABI patient in hospital. Neurorehabilitation can result in a speedy, efficient recovery with long-term benefits and a better quality of life”.
The judges commented: ‘We really liked the creative way Sacha made her points. She used her experiences to explain really simply how neurorehabilitation works and what the benefits are to the patient and family. ”
Chris Bryant, MP for the Rhondda Valley and Chair of the All-Party Parliamentary Group for Acquired Brain Injury announced Sacha as the winner of the award on Monday 13th July. He said: “We are really struck by the fact that nearly every department of government needs to take into account the numbers of people they represent who are affected by brain injury. We need people, like Sacha, to share their stories to get our message across.”
Rachael Chamberlain, Business Development Director at Cygnet Health Care said: “Cygnet is delighted to be sponsoring the UKABIF Film Award. Neurorehabilitation has a key role in the patient care pathway following an ABI. We will use the film as part of our induction training programme for new staff as it explains the importance of neurorehabilitation so clearly and simply.”
You can also see UKABIF’s Chair, Dr Andrew Bateman, Cygnet’s Rachael Chamberlain and Chris Bryant presenting Sacha with the UKABIF film award here (https://www.youtube.com/watch?v=WTTTAkIZS58)
The film will be shared widely across social media to help explain simply what neurorehabilitation involves and why it works.
Neurokinex, a specialist paralysis rehabilitation charity with sites at Gatwick, Hemel and Bristol, is running an online auction for two weeks from noon on Friday July 17th until noon on Friday July 31st to raise funds to safeguard the future of its Newly Injured Scheme.
The auction includes a wide choice of lots including sports and popular culture memorabilia, iconic art, UK experiences and short breaks at home and abroad.
Particular highlights include:
A Beatles display signed by all four members of the band
Jonny Wilkinson signed England rugby shirt
Limited edition David Bowie portrait
Raymond Blanc cookery lesson for two
Anthony Joshua signed boxing glove
Ascot and Lord’s Pavilion experiences
Rafael Nadal signed tennis racquet
Andy Warhol’s famous Marilyn Monroe portrait
Other lots including a champagne tea in London, a hand-drawn pet portrait, Lake District break, a castle stay in Bordeaux and a Gin Club membership ensure there really is something for all tastes and budgets.
The auction is the finale of the two-month Neurokinex Step Up Appeal – an emergency fundraising effort with a target of £25,000 – to secure vital services for people with a newly acquired spinal cord injury. Prior to the Covid-19 lockdown, Neurokinex operated a Newly Injured Scheme which awards six free sessions to those newly injured or diagnosed and referred by the NHS. The service is a lifeline for many, giving them access to the unique Neurokinex services that can have life-changing results. It costs Neurokinex £420 per person but, sadly, following lost income over the lockdown, without additional fundraising it is now under serious threat of being withdrawn.
“It’s great to have facilities that spinal cord injured individuals can access after their inpatient hospital admission has come to an end. The six free sessions on offer at Neurokinex for new injuries is a hugely important resource that helps to bridge the gap between discharge and access to community professionals facilitating community reintegration. The feedback received from returning patients, having been treated by Neurokinex, is that the team is fun and dynamic. They all see Neurokinex as a very important part of their long-term rehabilitation and fitness regime, so it’s vital we continue to ensure we can keep services like theirs running.”
Kirsten Hart, Clinical Specialist Physiotherapist at Stoke Mandeville Hospital
“Now, more than ever before, we need support from the public and hope that our Step Up Appeal will raise the necessary funds to keep our referral service going,” says Harvey Sihota, founder and director of Neurokinex. “We have a waiting list of hopeful beneficiaries who are waiting for their rehabilitation with us to begin. Our hope is that this silent auction will boost our Step Up Appeal funds to enable people to start on our programme without delay.”
The Hereditary Spastic Paraplegia (HSP) Support Group is a small UK charity run by volunteers. It aims to provide support to those with HSP, their families and their carers. The group creates a friendly community allowing its members to feel less isolated and share their stories with each other.
The charity regularly runs local meetings across the country, with a larger AGM in July. They publish a newsletter 2-3 times a year and keep their website up to date (https://hspgroup.org/). They also have a private Facebook page, which can be accessed (https://www.facebook.com/hspgroup.org/), where members can discuss anything they want.
Members can apply for funding for mobility aids or other equipment to improve their quality of life. Members fundraise and the charity are proud of their annual Potato Pants Festival (http://potatopantsfestival.co.uk/). They also provide research grants to promote HSP research, part funding two UK PhDs this year.
The charity are striving to make themselves better known to relevant healthcare professionals, so that patients with HSP can be directed to them for support. They are there for the whole journey, not just the diagnosis, and would appreciate if healthcare professionals can:
Advertise the group to patients/carers with HSP under your care and your colleagues
Become honorary members of the group
Help to identify guest speakers for their meetings
Apply for small research grants which can be provided annually
On 18th June, the British Neuroscience Association (BNA) released its survey results into the future of neuroscience after COVID-19, raising serious concerns over the future of vital research into the nervous system and its disorders.
Over 400 neuroscience researchers UK-wide responded to the survey, representing a variety of neuroscience research settings and career stages. The findings show a significantly high number of researchers have been affected by the impact of COVID-19, with nearly a third of researchers considering leaving neuroscience as a result.
Commenting on the survey results, BNA President, Annette Dolphin, said: “It’s vital we understand the effect that the COVID-19 pandemic is having on current neuroscience research and on the future of the field. The range of concerns and issues highlighted by this survey shows the uncertainty facing neuroscientists, and the potentially devastating impact on this essential research into the nervous system and its disorders.
“Early in lockdown, the BNA wrote to research funders requesting they provide further support in order to keep neuroscience research on track. Going forward, the results of our survey provide important insight into how we can best represent the voice of the neuroscience community with universities, funders, employers and government, and provide the support researchers need, now and in the future.”
What some of our respondents are saying. . .
I might be forced out of science. My fellowship was for 20 months, I was 5 months in when the labs were closed – I’m not sure I’m going to get enough data for papers and follow on funding.” Early Career Research in molecular biology:
The uncertainty about when we can return to testing human participants will almost certainly have some seriously negative consequences for me and my research, but I am more concerned about how it is going to affect my junior colleagues: to our knowledge our PhD students’ studentships are not going to be extended to compensate for time lost unable to collect data. This is a very significant weight to expect our junior colleagues to shoulder.” Lecturer in human experimental medicine
[I’m considering] changing research type from face-to-face/neuroimaging to more distanced and qualitative work” Postgraduate researcher in human behaviour
I think a lack of funding opportunities could make it very difficult for early career researchers to progress in academia. There will be less opportunities and if they are competing against labs which are already established it will be very difficult to win grants. The knock-on effect is that they stay in postdoc positions (which there will be less available of) and they may out-compete newer postdocs based on experience or they leave research. The government must increase funding to help mitigate the impact of COVID-19. If the pandemic has done nothing, it has highlighted how crucial scientists are and they must be supported during this difficult time.” Early Career Researcher in animal behaviour
Equip stroke survivors’ who have aphasia with the skills they need to get online and use tools, such as Skype, WhatsApp, Facebook and Zoom, so they can keep in touch with family and friends
Enable stroke survivors to connect with the stroke survivor community
This new digital guide has been designed following a UK-wide consultation of stroke survivors’ with aphasia2. It contains helpful information and step-by-step guidance on how to get online and search the internet. The guide uses aphasia-friendly text supported by pictures and key words. It can be used with a text reader and covers the use of many devices; computer, laptop, tablet and smart phone. It is the first element in a suite of digital resources for people affected by aphasia which the Stroke Association are producing.
As many as 350,000 stroke survivors with aphasia, a common communication disability, are at greater risk of becoming lonelier and more isolated during the pandemic, according to the Stroke Association1. While people across the UK have been able to keep in touch with their loved ones thanks to technology, the charity is now highlighting the struggle that stroke survivors’ with aphasia face getting online.
Aphasia is a language and communication disorder, of which stroke is the most common cause. There are 1.2 million stroke survivors’ in the UK and around a third (33%) have aphasia1. Aphasia can affect a person’s ability to speak, read, write – and sometimes understand speech and use numbers. Aphasia affects language not intellect.
Pat Sweetingham (57) from Basingstoke, Hampshire had a stroke in June 2003 which left her with aphasia and epilepsy.
Pat said: “Aphasia can feel like an invisible disability. I can talk but I couldn’t write and reading is hard. Aphasia has been hard. At first I could not talk at all. I just had a few words. When you say you have aphasia most people do not know what you are talking about. Simple tasks like getting the bus, following directions or ordering coffee were challenging but have improved over time. Some days are better than others. Some days I am tired and it makes it worse.
“Technology will not be for everyone and some people will need extra support to use it. People with aphasia must be allowed to try things out for themselves and see what works for them. One person might find a tablet easy to use while another person would prefer a laptop. Lockdown has been especially hard for people with aphasia.
“My stroke group has been using online video calls to keep in touch but this does not work for everyone. We have a few members who are on their own and they do not know how to even use a computer. They have no one to talk to and have been cut off from their normal support. We have 6 group members who are now using video call. It makes a difference to all of the group members to connect with others who understand what they are going through. Our members enjoy coming to the group because they feel normal.
“People with aphasia have smaller social circles and lockdown has taken away many of their support lifelines like the gym, grandkids or their stroke groups. They have no one to talk to and have been cut off from their normal support.”
Juliet Bouverie, Chief Executive of the Stroke Association said: “When stroke strikes part of your brain shuts down and so does part of you. A third of stroke survivors have aphasia, which can rob you of your ability to read, write or speak. This pandemic has created an epidemic of loneliness, particularly among stroke survivors with aphasia. Everyone’s world has shrunk due to the pandemic but imagine the agony of being confined to the walls of your own head.”
According to the Revealing Reality report (2019)3 commissioned by the charity, stroke survivors with aphasia said their disability was misunderstood by those close to them, as well as by the wider community. They also reported that isolation had negatively impacted their mental health and well-being, leaving them frustrated and low in confidence. The charity fears that aphasia may lead people to withdraw further from friends and family, putting them at even greater risk from isolation during the pandemic.
Juliet continues: “You don’t have to feel imprisoned by aphasia. This guide provides a vital lifeline and gives you the skills and confidence to get online. It’s particularly helpful for keeping in touch with loved ones, guiding you through things like video calling. Aphasia doesn’t go away and that’s why we’ve developed a tool to help overcome the challenges that you might face.
You don’t have to feel imprisoned by aphasia.
Juliet Bouverie, Chief Executive of the Stroke Association
“It opens up a world of opportunities that may not have been previously accessible to stroke survivors with aphasia. I’m urging you to use and share this guide. If you’re a stroke survivor with aphasia who needs help getting the guide or would like a printed version, please contact the Stroke Helpline (0303 3033 100). Stroke is a lonely experience, but we’re here to support you to rebuild your life after stroke. The guide will also help you to access My Stroke Guide an online community of stroke survivors where you can share experiences, ask questions and find solutions.”
Kamini Gadhok MBE, Chief Executive of the Royal College of Speech and Language Therapists said: “We know that a third of stroke survivors have aphasia and problems communicating and understanding how to use those little things that we take for granted, such as online technology to keep in touch with others. Even being able to read a phone number can be a huge struggle. These barriers often leave individuals feeling isolated and alone, so this new tool will help them to stay in touch with loved ones, keep connected with friends and find support from the aphasia community.”
2. Aphasia Suite (2018): Consultation with People with Aphasia. Report for the Stroke Association on the Consultation with People who have Aphasia.*
3. Revealing Reality (2019). Life with aphasia – Stage 2 report.*
*These reports are not yet publicly available. If you would like further information please contact: Sokina Miah PR & Media Officer at the Stroke Association at Sokina.miah@stroke.org.uk
Biogen launches ACT Myself – a free digital self-help tool to support the mental health of people living with multiple sclerosis (MS) as NHS highlights rise in anxiety among patients
Biogen has launched a free, new, digital self-help tool to help people living with multiple sclerosis (MS) navigate the emotional challenges of life with the disease. The tool, named ACT MySelf, was developed by Biogen in collaboration with people living with MS, the MS Trust, a team of MS specialist nurses and an MS clinical psychologist. The tool has been developed in response to UK research revealing the emotional pressure points experienced by people living with MS, particularly at diagnosis and early in the disease1.
Recent data from the NHS and the MS Trust have also suggested that the number of people living with MS experiencing these emotional pressure points may be increasing2,3. In 2019 alone, the NHS reported a 24.5% rise in anxiety disorders amongst people living with MS3, and a recent survey published by the MS Trust revealed that 72% of people living with MS report that they have felt anxious or depressed for more than several days a month2.
With the rise in anxiety levels among the general population following the COVID-19 lockdown4, and the increased pressure on healthcare professionals during the pandemic, utilisation of self-help digital tools, such as ACT MySelf can help provide additional support to those living with MS, as well as MS nurses, neurologists and mental health services.
“It is deeply concerning that so many people affected by MS are not receiving the emotional support they need. Living with a long-term condition like MS does not only mean facing physical challenges, it can mean overcoming mental challenges too, and we believe it is absolutely vital that the support and information is out there to help people with MS, and loved-ones, who are struggling with their mental health,” said David Martin, Chief Executive at the MS Trust and Vice Chair of the Neurological Alliance.
ACT MySelf guides people through exercises based on Acceptance and Commitment Therapy (ACT), a validated psychological therapy that is used in the management of conditions such as anxiety, depression and pain, and which has been shown to benefit people living with MS5. The tool helps people to learn strategies to live life more in the present, with more focus on what’s important to them and less focus on painful thoughts, feelings and experiences6.
“There is often limited resource within MS services dedicated to psychological or emotional support. We developed the ACT MySelf tool to help address this, as a widely available tool for those who do not require specialist intervention. It’s an easy-to-use resource, incorporating simple exercises that those living with MS may benefit from to help them live a valued life,” said Carolyn Patterson, Clinical Psychologist, Ayrshire Central Hospital, NHS Ayrshire and Arran and one of the experts involved in developing ACT MySelf.
The tool was developed in response to research sponsored by Biogen, which revealed that people with MS in the UK experience feelings of anxiety, fear, confusion and uncertainty around key points in their diagnosis and treatment journey1. The research highlighted that women experience their MS very differently from men, with far more women reporting feeling fear when noticing symptoms or seeing a neurologist. However, men are much more prone to depression in the pre-diagnosis stage, at least three times as much as women1.
About ACTMySelf
ACT MySelf has been developed for people living with MS and any friends or family members who feel they could benefit from strategies to help them navigate the emotional impact of the disease. It can be accessed free of charge at www.actmyself.co.uk
The digital resource focuses on three areas: recognising emotions and being mindful of them, refocusing on what’s important in life, and creating goals centred on what matters.
The digital resource is not intended to replace professional psychological support and people living with MS should discuss their psychological and emotional wellbeing with their healthcare team.
About CleoTM
CleoTM is a free health and wellbeing app designed to provide information and support for anyone living with MS as well as their carers, family and friends. For more information, visit: www.cleo-app.co.uk
• BIAL released opicapone data from seven abstracts at the European Academy of Neurology (EAN) virtual congress • Data from BIPARK-I and II post-hoc analysis show opicapone 50 mg is effective in patients with Parkinson’s disease (PD) regardless of duration of motor fluctuations • Additional data suggest potential for opicapone as first-line adjunctive levodopa/ DDCI (DOPA decarboxylase inhibitor) treatment in patients with motor fluctuations, who cannot be stabilised by levodopa/ DDCI alone
New data was presented at the 6th congress of the European Academy of Neurology, demonstrating the potential for ONGENTYS® (opicapone) to help a wide range of Parkinson’s patients with motor fluctuations.
A new post-hoc analysis of two large multinational trials (BIPARK-I and II1,2) shows that opicapone, a once-daily COMT (catechol-O-methyltransferase) inhibitor, demonstrated efficacy in both patients recently diagnosed with motor fluctuations (duration of motor fluctuations up to 1 year) and long-standing motor fluctuators (duration of more than 1 year) as measured by changes from baseline in absolute OFF- and ON-time versus placebo.3 COMT inhibitor treatment is appropriate for patients taking levodopa where there is evidence of motor fluctuations such as ‘wearing-off’. This can occur earlier in the course of the illness than was previously recognised.4
Dyskinesia was the most frequently reported ‘at least possibly’ related treatment- emergent adverse event. Patients receiving opicapone 50 mg had a lower incidence of dyskinesia if they were recently-diagnosed versus long-standing motor fluctuators.3
Professor Joaquim Ferreira, Professor of Neurology and Clinical Pharmacology at the University of Lisbon, said, “Opicapone demonstrated efficacy in both recently-diagnosed and long-standing motor fluctuations. This reinforces the benefit of opicapone regardless of duration of motor fluctuations and suggests it could be considered as soon as end-of-dose motor fluctuation commences.”
The potential for earlier use of opicapone in some patients was also supported by additional data released at EAN demonstrating efficacy in patients with motor fluctuations treated with levodopa/DDCI-only (that is, without use of dopamine agonists or MAO-B inhibitors) in a posthoc analysis of BIPARK-I and II.5
“BIAL is committed to providing new therapeutic solutions and is proud of the wealth of opicapone data being released at EAN” said António Portela, CEO of BIAL. “Our focus is on providing an effective option for patients on levodopa who may be experiencing motor fluctuations at any stage of treatment. These data, along with real-world evidence from the recently published OPTIPARK study, also presented at EAN, show the potential for opicapone in clinical practice.”
Data on opicapone at the EAN were presented in 11 abstracts, seven of these were sponsored by BIAL:
EPO1224: Ebersbach G et al. Efficacy and Safety of Opicapone in Parkinson’s Disease Patients According to Duration of Motor Fluctuations: Post-Hoc Analysis of BIPARK-I and II3
EPR1141: Ferreira JJ et al. Opicapone as First-Line Adjunctive Levodopa Treatment in Parkinson’s Disease Patients with Motor Fluctuations: Findings from BIPARK-I and II Combined Post-Hoc Analysis5
EPO1182: Antonini A et al. Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson’s Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II
EPR2111: Reichmann H et al. Opicapone in Clinical Practice in Parkinson’s Disease Patients with Motor Fluctuations: Findings from the OPTIPARK Study
EPO3148: Rascol O et al. Efficacy of Opicapone in Patients with Parkinson’s Disease with Levodopa Dose Reduction: A Pooled Post-Hoc Analysis of BIPARK-I and II
EPO3141: Poewe W et al. Change in OFF-/ON-Time After Switching from Double-Blind Entacapone or Placebo to Open-Label Opicapone in Patients who Ended the 1-Year BIPARK-I Extension Study on Opicapone 50-mg
EPO3175: Tolosa E et al. Changes Activities of Daily Living and Motor Function in Patients Switching from Entacapone or Placebo to Opicapone who Ended BIPARK-I Extension on Opicapone 50-mg
BIAL announced on 29th April 2020 that the U.S Food and Drug Administration (FDA) has approved ONGENTYS® (opicapone) as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.
We are very pleased to achieve this major regulatory milestone for opicapone, which offers patients living with Parkinson´s disease an effective, once-daily adjunctive treatment option to the gold standard levodopa/dopa-decarboxylase inhibitors preparations. This approval is a landmark in BIAL’s ongoing commitment to the quality of life of Parkinson’s patients and their caregivers. We look forward to working with our partner in the U.S., Neurocrine Biosciences, to make this therapy available to patients.
António Portela, CEO of BIAL.
In February 2017, BIAL and Neurocrine Biosciences entered into an exclusive licensing agreement for the development and commercialisation of opicapone in the U.S. and Canada. The commercial launch of opicapone in the U.S.is expected to occur later in 2020.
The FDA approval of opicapone is supported by data from 38 clinical studies, including two multinational Phase III clinical studies (BIPARK-1 and BIPARK-2). In BIPARK-1, a randomized, double-blind placebo- and active-controlled study, approximately 600 patients with Parkinson’s disease and end-of-dose motor fluctuations received once-daily doses of opicapone (5 mg, 25 mg, or 50 mg), placebo or 200 mg of the COMT (catechol-O- methyltransferase) inhibitor entacapone for 14 to 15 weeks as adjunct to levodopa therapy. In BIPARK-2, which followed a similar study design, approximately 400 patients received once- daily doses of opicapone (25 mg or 50 mg) or placebo.
The primary endpoint for both studies was the change from baseline in absolute time in the OFF state, as assessed by patient diaries. The initial study period in each BIPARK was followed by a one year open-label phase during which all eligible patients received treatment with opicapone. Treatment with opicapone 50 mg was found to be superior to placebo in both studies. The beneficial effects of opicapone 50 mg at reducing the time in the OFF state were accompanied by a corresponding increase in time in the ON state without troublesome dyskinesia. Results from both open-label phases indicated a maintenance of effect for patients previously treated with opicapone 50 mg. Overall, opicapone was found to be generally well tolerated. Primary outcomes from the BIPARK-1 study are published in Lancet Neurology1, with the outcomes from the open-label extension phase published in Neurology2. Primary outcomes from the BIPARK-2 study and the open-label extension are published in JAMA Neurology3.
References
Ferreira J., et al. Lancet Neurol. 2016 Feb;15(2):154-165
Ferreira J., et al. Neurology. 2018 May 22;90(21):e1849-e185 3. Lees A., et al. JAMA Neurol. 2017 Feb 1;74(2):197-206
Opicapone is a once-daily, peripherally-acting, third-generation, highly-selective COMT inhibitor.
Opicapone works by decreasing peripheral levodopa’s conversion rate into 3-O-methyldopa, thereby prolonging the duration of levodopa’s effect in reducing the OFF-time period of Parkinson’s and extending the ON-time period.
In June 2016, the European Commission authorized Ongentys® (opicapone) as an adjunct therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilized on those combinations. In Europe opicapone is currently marketed in Germany, United Kingdom, Spain, Portugal and Italy.
About BIAL
Founded in 1924, BIAL’s mission is to research, develop and provide therapeutic solutions within the area of health. In the last decades, BIAL has focused strategically on quality, innovation and internationalisation. BIAL is strongly committed to therapeutic innovation, investing more than 20% of its annual turnover into research and development within neurosciences and the cardiovascular system. The company expects to introduce new drugs on the market in the coming years, strengthening its international presence based on proprietary drugs and achieving its goal of supplying innovative products to patients worldwide.
With the non-stop influx of scientific data in neurology, healthcare professionals often struggle to stay up to date on the latest developments by searching through multiple journals and pouring through lengthy articles in search of new advances.
To address the challenge, Biogen Inc. established a single, online platform that aggregates high-quality scientific content in 18 neurology topics, in digestible format. The service was developed by listening to neurologists’ needs through extensive desk research, interviews, prototype testing and ongoing user feedback to ensure the service is relevant and constantly improving.
Called Neurodiem, the non-promotional digital platform from Biogen Inc. is available in six languages and is now live in the United Kingdom, United States, France, Germany, Italy, Spain, Canada and Japan. The scientific information on the platform is entirely objective and independent from Biogen. It is selected, written, and published exclusively by independent scientific writers and editorial partners, who endure ongoing relationships with faculty from academic institutes, and hospitals worldwide. In 2020, the platform features over 3000 daily summaries from key publications, exclusive presentations and interviews from over 70 key medical experts on emerging topics, real-time highlights from 13 international neurology conferences, and access to over 900 full-text articles from renowned neurology journals.
COVID-19 has forced us to use more online resources to keep ourselves up-to-date,” says Rhys Davies, Consultant Neurologist, Liverpool.
I had not previously made much use of online video lectures. However, now I’ve discovered neurodiem.co.uk I find, in particular, its “library” of short lectures from key opinion leaders very useful, in terms of subject selection, content and format!”
More than 7,000 healthcare professionals, including over 4000 neurologists, registered to the platform worldwide in less than one year. For 2020, Biogen Inc. plans on launching the Neurodiem App in the UK to ease access of information on the go. Additionally, the digital team behind the platform is strongly focusing on improving the user experience through advanced personalisation, as a means to provide healthcare professionals in neurology with the best and most convenient service to stay up-to-date in their ever-evolving field.
Learn more on www.neurodiem.co.uk. Neurodiem is free and exclusive to healthcare professionals.
Neurodiem is a service provided by Biogen MA Inc. The information presented on Neurodiem will in no way be selected, modified or altered by Biogen.
Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified.
